Villanueva-Peñacarrillo M L, Alcántara A I, Clemente F, Delgado E, Valverde I
Department of Metabolism, Nutrition and Hormones, Fundacióń Jimenez Diaz, Madrid, Spain.
Diabetologia. 1994 Nov;37(11):1163-6. doi: 10.1007/BF00418382.
GLP-1(7-36)amide is an intestinal post-translational proglucagon product released mainly after carbohydrate ingestion, the glucose dependent insulinotropic and antidiabetogenic actions of which have been documented. In this work, by exploring whether GLP-1(7-36)amide has any effect on the glucose metabolism of the muscle, we have observed that this peptide, at physiological concentrations, exerts in this tissue an increment of the D-[U-14C]glucose incorporated into glycogen, which is accompanied by an increase in the glycogen synthase a activity; also, it stimulates both glucose oxidation and lactate formation. These data indicate that the skeletal muscle is one of the target tissues for GLP-1(7-36)amide, where its insulin-like effect explains, at least in part, its plasma glucose lowering action; thus, GLP-1(7-36)amide may well be implicated in the physiological control of glucose homeostasis after meals, not only by acting as an incretin, but also by directly promoting glucose disposal.
胰高血糖素样肽-1(7-36)酰胺是一种肠道翻译后胰高血糖素原产物,主要在摄入碳水化合物后释放,其葡萄糖依赖性促胰岛素分泌和抗糖尿病作用已有文献记载。在本研究中,通过探究胰高血糖素样肽-1(7-36)酰胺对肌肉葡萄糖代谢是否有任何影响,我们观察到,在生理浓度下,该肽在该组织中可使掺入糖原的D-[U-14C]葡萄糖增加,同时糖原合酶a活性增加;此外,它还刺激葡萄糖氧化和乳酸生成。这些数据表明,骨骼肌是胰高血糖素样肽-1(7-36)酰胺的靶组织之一,其胰岛素样作用至少部分解释了其降低血糖的作用;因此,胰高血糖素样肽-1(7-36)酰胺很可能不仅通过作为肠促胰岛素,还通过直接促进葡萄糖处置参与餐后葡萄糖稳态的生理调节。